Please login to the form below
pediatrics
This page shows the latest pediatrics news and features for those working in and with pharma, biotech and healthcare.
Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more
Orchard gains rare disease status for ex-GSK therapy. Orchard Therapeutics has been granted an FDA Rare Pediatric Disease Designation for its rare disease gene therapy candidate OTL-200, which it
Latest news
-
Dr Reddy's brings its generics portfolio to France
Meanwhile, in its home country it is targeting a number of therapy areas, having agreed a 118m deal with UCB in 2015 to acquire a portfolio of dermatology, respiratory and pediatric
-
Lilly pilots enhanced online trial information
The pilot project has so far been added to two clinical trials, a study of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis and one of Cialis (tadalafil) in pediatric patients with
-
Biogen buys into Ionis' nusinersen after positive phase III trial
Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months”
-
Celebrating excellence
The programme saw Novo work in partnership with Roche, the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF).
-
PMEA 2015 win for Novo's Changing Diabetes in Children
The programme saw Novo work in partnership with Roche, the International Society for Pediatric and Adolsecent Diabetes (ISPAD) and the World Diabetes Foundation (WDF).
More from news
Approximately 1 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Implementing eHealth innovation
The first results from the global, five-year observational study in children with growth disorders was presented at the 10th International Meeting of Pediatric Endocrinology in September 2017.
-
Paging Dr Millennial
Almost 50% of the world's population today is under 25 years old, which means that family planning, women's health and pediatrics will be growing elements of the world's
-
Pharma deals in August 2015
In 2012 the PRV programme was extended to include rare pediatric diseases and the emergence of trading in PRVs was noted in our last annual Deal Watch report.
-
Pharma deals during November 2014
In 2012 the PRV programme was extended to include rare pediatric diseases. ... BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological product for patients with Mucopolysaccharidosis type IVA.
-
Pharma deals during March 2013
825. Edison Pharmaceuticals/ Dainippon Sumitomo. Licence. EPI-743 (orphan pediatric mitochondrial disease) and EPI-589 (adult CNS disease) (phase II).
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
As a trained pediatric oncologist, Fouad brings to this role exceptional clinical experience and an unwavering commitment to patients. “
-
Dr Andrew Mulberg moves from FDA to Amicus Therapeutics
Dr Mulberg is a pediatric gastroenterologist, and was attending physician and fellowship director in gastroenterology and hepatology for The Children's Hospital of Philadelphia between 1993 and 2001. ... He is currently the board chairman and member of
-
Former PEPFAR head Mark Dybul to lead the Global Fund
In addition to his new post, Dr Dybul currently serves as a director on several executive and advisory boards of health organisations, including Malaria No More, the Elizabeth Glaser Pediatric AIDS
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Mastering the precision medicine opportunity
Last year the FDA made a pioneering move in this space and approved Keytruda for use in adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
-
Senior Medical Writer
-
Salary is DOE
- Account Director or Senior Account Director
-
Salary TBC
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Sudler London - Senior Medical Writer
-
Competitive
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
Subscribe to our email news alerts
- Tox trouble stalls Sosei/Allergan Alzheimer’s drug
- London cancer hub launched by Cancer Research UK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Making a Difference - The Future of Pharma
- AZ prepares to file COPD triple, taking on rival GSK
- Controversy grows around GP at Hand service after minister’s endorsement
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
